CRC
TEVA icon

Curi RMB Capital’s Teva Pharmaceuticals TEVA Stock Holding History

Curi RMB Capital’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-7,255
Closed -$388K – 505
2016
Q1 		$388K Sell
7,255
-6,338
-47% -$372K 0.03% 290
2015
Q4 		$893K Sell
13,593
-20,361
-60% -$1.26M 0.04% 249
2015
Q3 		$1.92M Sell
33,954
-8,886
-21% -$576K 0.13% 180
2015
Q2 		$2.53M Buy
42,840
+100
+0.2% +$6.17K 0.16% 137
2015
Q1 		$2.66M Sell
42,740
-2,651
-6% -$154K 0.16% 145
2014
Q4 		$2.61M Sell
45,391
-6,884
-13% -$384K 0.16% 144
2014
Q3 		$2.81M Sell
52,275
-2,451
-4% -$130K 0.17% 141
2014
Q2 		$2.87M Sell
54,726
-1,240
-2% -$63.4K 0.18% 134
2014
Q1 		$2.96M Sell
55,966
-6,602
-11% -$305K 0.2% 121
2013
Q4 		$2.51M Sell
62,568
-6,753
-10% -$266K 0.17% 136
2013
Q3 		$2.62M Buy
69,321
+2,995
+5% +$117K 0.19% 134
2013
Q2 		$2.6M Buy
+66,326
New +$2.58M 0.2% 122

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Curi RMB Capital's TEVA Position: Q2 2016 in Review

Curi RMB Capital sold out of Teva Pharmaceuticals (TEVA) in Q2 2016, closing a stake of 7,255 shares — an estimated $388K sold.

Curi RMB Capital first reported a position in TEVA in Q2 2013 and held it in 12 quarters. The position peaked at $2.96M in Q1 2014. 812 funds tracked by Wall St. Rank hold TEVA as of Q2 2016.

  • Curi RMB Capital reported no remaining Teva Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • Curi RMB Capital sold 7,255 Teva Pharmaceuticals shares in Q2 2016, an estimated $388K.
  • Curi RMB Capital first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 12 quarters.
  • Curi RMB Capital's Teva Pharmaceuticals position peaked at $2.96M in Q1 2014.
  • 812 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2016.

Based on Curi RMB Capital's 13F filing for Q2 2016, filed 3 Aug 2016.